^
    MET N375S
    Salivary Gland Cancer
    crizotinib + pazopanib
    Sensitive
    :
    C3
    Onco Targets Ther - 4d
    HER-2 positive
    Salivary Gland Cancer
    trastuzumab
    Sensitive
    :
    A2
    No biomarker
    Salivary Gland Cancer
    cisplatin + doxorubicin hydrochloride + cyclophosphamide oral
    Sensitive
    :
    A2
    No biomarker
    Salivary Gland Cancer
    cisplatin + vinorelbine tartrate
    Sensitive
    :
    A2
    NTRK2 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Salivary Gland Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Salivary Gland Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Salivary Gland Cancer
    entrectinib
    Sensitive
    :
    A2
    AR positive
    Salivary Gland Cancer
    leuprolide acetate
    Sensitive
    :
    A2
    AR positive
    Salivary Gland Cancer
    bicalutamide
    Sensitive
    :
    A2
    PD-L1 expression
    Salivary Gland Cancer
    pembrolizumab
    Sensitive
    :
    C1
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab
    Sensitive
    :
    C1
    RET fusion
    Salivary Gland Cancer
    selpercatinib
    Sensitive
    :
    C1
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab
    Sensitive
    :
    C2
    AR positive
    Salivary Gland Cancer
    leuprolide acetate + bicalutamide
    Sensitive
    :
    C3
    PLIN2 expression
    Salivary Gland Cancer
    leuprolide acetate + bicalutamide
    Sensitive
    :
    C3
    AKT1 E17K
    Salivary Gland Cancer
    AZD5363
    Sensitive
    :
    C3
    HER-2 expression
    Salivary Gland Cancer
    ARX788
    Sensitive
    :
    C3
    HRAS mutation
    Salivary Gland Cancer
    tipifarnib
    Sensitive
    :
    C3
    HER-2 amplification
    Salivary Gland Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    C3
    HER-2 expression
    Salivary Gland Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    C3
    PTEN expression
    Salivary Gland Cancer
    bicalutamide
    Sensitive
    :
    C3
    PTEN expression
    Salivary Gland Cancer
    trastuzumab
    Sensitive
    :
    C3
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES